Company profile
PROVECTUS BIOPHARMACEUTICALS, INC. CIK 315545
Ticker
PVCT (OTC)
Industry
Pharmaceutical Preparations
Headquarters
Knoxville, TN 37929
Fiscal year end
2025 (FY)
Key Financials
Revenue
$336.1K
Net income
-$5.43M
Total assets
$697.5K
Total liabilities
$7.00M
Stockholders' equity
-$6.30M
Cash & equivalents
$251.3K
Operating income
-$5.29M
Operating cash flow
-$3.33M
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2026-03-26. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
-1,575.3%
Net margin
-1,615.8%
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
1,003.6%
Equity / assets
-903.0%
CapEx / revenue
—
Operating cash flow / net income
0.61×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
$336.1K
-$5.43M
$697.5K
$7.00M
-$6.30M
2024
$617.1K
-$4.73M
$1.01M
$6.98M
-$5.96M
2023
$557.7K
-$3.10M
$1.45M
$9.04M
-$7.59M
2022
$989.0K
-$3.55M
$2.04M
$8.27M
-$6.23M
2021
—
-$5.54M
$3.51M
$7.70M
-$4.19M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 4
2026-09-18
Financials filed via
Form 10-K
filed 2026-03-26
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Knoxville, TN 37929
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:53 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.